← Human Trials & Peer-Reviewed Studies
Brain potential signs of slowed stimulus processing following cholecystokinin in Parkinson's disease
Plain-language guide to PMID 11967633 (2002): double-blind and placebo-controlled controlled clinical trial study of Cholecystokinin (CCK), parkinson's disease.
Key Facts
- PMID
- 11967633
- Journal
- Psychopharmacology
- Year
- 2002
- Study type
- Controlled Clinical Trial
- Authors
- Smolnik R et al. (6 authors)
- DOI
- 10.1007/s00213-002-1010-9
What This Study Did, in Plain Language
What Was Tested
Researchers studied Cholecystokinin (CCK) in the context of parkinson's disease in this controlled clinical trial publication.
The present study examined the effects of a single intranasal administration of CCK-8 on auditory brain potential (AEP) signs of cognitive processing and on motor performance in patients with Parkinson's disease (PD), known to originate from degeneration of DA neurons primarily in the nigrostriatal DA system.
Why It Was Studied
Cholecystokinin (CCK) is a neuropeptide which is colocalized with dopamine (DA) in neurons of the mesolimbic-frontocortical and nigrostriatal DA system.
In animals CCK enhances DA activity in these systems.
Who Took Part
PubMed indexes the participants as middle-aged adults and older adults, both men and women.
Thirteen PD patients were examined after medication withdrawal, on two occasions after administration of placebo and 25 microg CCK-8, and compared with healthy controls matched for age and sex.
AEPs were recorded while subjects performed an attention task (oddball paradigm).
How the Study Was Run
In design terms this was a double-blind and placebo-controlled study.
Neither the participants nor the staff measuring them knew who was on Cholecystokinin (CCK), so expectations could not easily colour the readings.
Some participants received a placebo instead of Cholecystokinin (CCK), giving a reference point.
What Was Measured
Topics PubMed links to this paper include Brain, Cholecystokinin, Cognition, Evoked Potentials, Auditory, Motor Activity, Parkinson Disease and Reaction Time.
What This Means in Plain Language
The paper is a double-blind and placebo-controlled study of Cholecystokinin (CCK) in people with parkinson's disease.
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2002 (Psychopharmacology), a journal based in Germany.
More context: the Cholecystokinin (CCK) compound page, Parkinson's disease research.
Our Notes on the Compound
Cholecystokinin (CCK): A gut and brain peptide hormone that stimulates gallbladder contraction and signals fullness.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.